GlassScriptPhysician profile
Reid K Sullivan
NPI 1376349399
$1,353.90
in general payments reported to CMS, 2019-2025
22 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $98.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.86 |
| Education | $98.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.39 | 2025 | Imfinzi, Lynparza, Calquence |
| Lilly USA, LLC | $159.78 | 2025 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $146.19 | 2025 | Tecvayli, Talvey, Darzalex |
| Genentech USA, INC. | $104.09 | 2025 | Itovebi, Venclexta, Polivy |
| Pharmaessentia USA Corporation | $97.94 | 2025 | Besremi |
| Merck Sharp & Dohme LLC | $90.26 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Beone Medicines USA, INC. | $88.24 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $79.25 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $67.22 | 2025 | |
| Novocure INC. | $58.72 | 2025 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $42.91 | 2025 | |
| Abbvie INC. | $32.22 | 2025 | |
| Agios Pharmaceuticals, INC. | $29.84 | 2025 | Pyrukynd |
| Daiichi Sankyo INC. | $29.28 | 2025 | Enhertu |
| Eisai INC. | $28.53 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $24.89 | 2025 | |
| Accord Healthcare, INC. | $21.26 | 2025 | |
| Genzyme Corporation | $21.13 | 2025 | |
| Caris Mpi, INC. | $20.83 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $19.42 | 2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $14.09 | 2025 | Opdivo |
| Gilead Sciences, INC. | $12.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reid Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.